Yupelri is manufactured by Theravance Biopharma and Mylan N.V. [1][2]. Theravance Biopharma is the developer, and Mylan is the commercial partner for Yupelri in the United States [1].
Who Else Makes Yupelri?
While Theravance Biopharma developed Yupelvi, the commercial rights in the United States are held by Mylan N.V. [1].
What Is Yupelri Used For?
Yupelri is a long-acting muscarinic antagonist (LAMA) approved for the treatment of patients with tiotropium, inhaled, long-acting bronchodilator therapy [3]. It is indicated for patients with chronic obstructive pulmonary disease (COPD) [3].
When Does Yupelri's Patent Expire?
Information regarding the specific patent expiry dates for Yupelri is available through drug patent tracking services [4]. DrugPatentWatch.com provides comprehensive data on drug patents, including those for Yupelri, which can help determine when exclusivity is expected to end [4].
How Does Yupelri Work?
Yupelri, also known asrevefenacin, is a LAMA that works by blocking the action of acetylcholine on smooth muscle cells in the airways. This blockade leads to bronchodilation, helping to open up the airways and ease breathing for patients with COPD [3].
What Are the Side Effects of Yupelri?
Common side effects reported with Yupelri include nasopharyngitis (cold-like symptoms), diarrhea, nausea, vomiting, aphthous stomatitis (mouth sores), and urinary tract infections [3].
What Is the Difference Between Yupelri and Other COPD Medications?
Yupelri is a LAMA. Other common COPD medications include short-acting bronchodilators, long-acting beta-agonists (LABAs), and inhaled corticosteroids. LAMAs like Yupelri provide long-acting bronchodilation and are typically used as maintenance therapy for COPD [3]. The choice of medication often depends on the severity of COPD and individual patient needs.
How Much Does Yupelri Cost?
The cost of Yupelri can vary. Patients and healthcare providers can find pricing information through pharmaceutical manufacturers and prescription discount programs [1].
Are There Any Generics for Yupelri?
As of the information available, there are no generic versions of Yupelri on the market. Patent expiry dates will determine when generic alternatives may become available [4].
What Clinical Trials Were Conducted for Yupelri?
Yupelri's approval was based on data from two Phase 3, 6-month, randomized, double-blind, placebo-controlled studies. These studies evaluated the safety and efficacy of Yupelri in patients with moderate to very severe COPD. The primary efficacy endpoint was the change from baseline in the pre-dose FEV1 at day 84 [3].
What Regulatory Agencies Approved Yupelri?
Yupelri was approved by the U.S. Food and Drug Administration (FDA) [3].
---
1. "Theravance Biopharma Announces FDA Approval of Yupelri (revefenacin) Inhalation Solution for the Maintenance Treatment of Patients with COPD." Theravance Biopharma, 2018.
2. "Mylan and Theravance Biopharma Announce FDA Approval of Yupelri™ (revefenacin) Inhalation Solution for the Maintenance Treatment of Patients with COPD." Mylan N.V., 2018.
3. "YUPELRI (revefenacin) Prescribing Information." Mail code 7301.002, October 2018.
4. "Yupelri." DrugPatentWatch.com.